---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-23-001846"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2023-10-16T23:59:59+00:00"
generated_at: "2026-06-09T23:08:55.902427+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lexaria grants exclusive global license to SulfoSyn for DehydraTECH-sulforaphane non-pharmaceutical products

## Summary
- Up-front cash payment received; minimum future payments and ongoing royalties agreed.
- Lexaria contracted for manufacturing at US partner facility for initial 2-year term.
- DehydraTECH applied to sulforaphane, a compound with anti-inflammatory and antioxidant properties.
- Non-pharmaceutical uses include supplements, additives, foods, and dietary ingredients.
- SulfoSyn granted sub-licensing rights for the licensed technology.

## SEC filing metadata
- accession: 0001640334-23-001846
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2023-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033423001846/0001640334-23-001846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033423001846/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-23-001846
- JSON: https://secwatch.observer/filing/0001640334-23-001846.json
- Plain text: https://secwatch.observer/filing/0001640334-23-001846.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.